Quick Answer
Estrella Immunopharma, Inc. reported Total Assets of $3.18 million for the year ending 2025.
- Estrella Immunopharma, Inc. showed an increase of +1.2% in Total Assets from 2024 to 2025.
- This data is from Estrella Immunopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2021 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: $45.97 million | Q1 2022: $45.62 million | Q2 2022: $45.38 million | Q3 2022: $45.62 million | Q4 2022: $9.72 million | Q1 2023: $9.78 million | Q3 2023: $27.35 million | Q4 2023: $9.45 million | Q1 2024: $8.63 million | Q2 2024: $4.45 million | Q3 2024: $3.74 million | Q1 2025: $2.44 million | Q2 2025: $2.98 million | Q3 2025: $3.52 million.
- Over the full 6 years of available data (2021 to 2025), Estrella Immunopharma, Inc.'s Total Assets has declined by 93.1%.
- Historical annual values: Fiscal year 2025: $3.18 million | Fiscal year 2024: $3.14 million | Fiscal year 2024: $4.45 million | Fiscal year 2023: $3.03 million | Fiscal year 2022: $9.72 million | Fiscal year 2021: $45.80 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: